Abstract
The objective of this study is to report on our 5-year collective experience on the use of perhexiline in the UK, in patients with chronic heart failure (CHF) and/or refractory angina with respect to 'real-life' drug side effects and toxicity, therapeutic drug level monitoring, 5 year mortality outcomes and predictors of response to perhexiline therapy.
Original language | English |
---|---|
Pages (from-to) | 881-886 |
Number of pages | 6 |
Journal | European Journal of Heart Failure |
Volume | 11 |
Issue number | 9 |
Early online date | 20 Aug 2009 |
DOIs | |
Publication status | Published - Sept 2009 |
Keywords
- Chronic heart failure
- Refractory angina
- Perhexiline
- Mortality and drug monitoring